Airway Therapeutics

  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact

Airway Therapeutics Completes Enrollment in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

June 5, 2023 By Meghan Riley

  • Favorable safety profile confirmed also in fourth and final cohort including babies born at earliest gestational age of 23 to 24 weeks
  • Interim analysis is complete and full results are expected by October 2023
  • Company expects to begin a Phase 3 trial by end of 2023

ATLANTA, GEORGIA (June 5, 2023) – Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it successfully completed enrollment in its Phase 1b trial of zelpultide alfa for preventive use in very preterm infants at risk for bronchopulmonary dysplasia (BPD).

The last of 12 patients recruited into the fourth and final cohort of the study has been treated. These infants, born at 23 to <29 weeks received daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D). The fourth cohort began recruitment March 28, 2023, following a Data Safety Monitoring Committee (DSMC) report finding no safety concerns at the conclusion of the trial’s dose escalation portion, and included the extremely preterm neonates born as early as weeks 23 and 24.

“We are very pleased to report that the recruitment of the first clinical study with zelpultide alfa has been successfully completed according to protocol,” said Airway CEO and Chief Medical Officer Marc Salzberg, M.D. “This is another major step in the development of this novel drug for the prevention of BPD in very preterm born babies.”

An interim analysis of the Phase 1b has been completed, and full trial results are expected by October 2023. The company plans to begin a Phase 3 trial by the end of 2023 which will involve at least 80 hospitals in North America and across Europe.

As many as 2.5 million very preterm infants globally are at risk of developing BPD from lung damage caused by mechanical ventilation and oxygen support. Babies who develop BPD can suffer lifelong complications such as asthma and pneumonia as well as growth and developmental problems.

Zelpultide alfa is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune responses. The biologic is administered intratracheally during mechanical ventilation.

The Phase 1b trial is a randomized, blinded, air-sham controlled study to establish the safety and tolerability of zelpultide alfa. A total of 37 infants were enrolled at 20 hospitals in the U.S. and Spain. The 25 infants in the dose escalation portion were born at 25 weeks to <29 weeks gestational age. The FDA and European Medicines Agency have granted orphan drug status to zelpultide alfa.

About Airway Therapeutics

Airway Therapeutics is a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, beginning with the most vulnerable populations. The company is advancing zelpultide alfa, a novel recombinant human protein hSP-D that reduces inflammation and infection in the body while modulating the immune response. Zelpultide alfa is Airway’s first candidate in development for prevention of BPD in very preterm infants and for treatment of COVID/CAP in seriously ill mechanically ventilated patients.

Media contact:
Meghan Riley
riley@airwaytherapeutics.com

Filed Under: Press Releases

logo

Airway Therapeutics, Inc

1200 Johnson Ferry Rd, Suite 300
Marietta, GA 30068

513.770.9630

  • Privacy

Sitemap

  • Home
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact
Copyright © 2015 Airway Therapeutics, Inc. All Rights Reserved.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.
Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT
MENU
  • About Us
  • Pipeline
  • BPD
  • Respiratory & Inflammatory Diseases
  • News
  • Contact